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Abstract 
Glucuronidation of various endobiotic and xenobiotic compounds catalyzed by 
UDP-glucuronosyltransferase is the major clearance mechanism for different classes 
of drugs. Failure in glucuronidation would result in serious disorder such as Gilbert's 
syndrome. The UDP-glucuronosyltransferases can be categorized into different 
classes according to their sequence homology and substrate specificity. There are 
more than 20 UGTs found in human and more than 15 in rats. Recently, a new UGT 
isoform (UGTl A8) was identified in vitro and in vivo. There is no structure data with 
very little polymorphism information on UGTs. In this study, the biochemical and 
structural properties of UGTl A8 were studied. 
The 1593 base pair cDNA coding fragment of rat UGT1A8 was cloned into 
expression vector and transformed into the expression host. Different cell strains were 
tested. The protein was induced and purified using His-tag binding column and gel 
filtration chromatography. Characterization of the purified protein was attempted. The 
enzyme activity was tested. Also, mutants of the enzyme were constructed to 
determine some important residues related to the enzymatic function. In addition, 
computer modeling and simulation of substrates-protein interaction was done. 
In the study, the rat UGT1A8 recombinant protein was successfully expressed in 
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E.coli cell strain JM109(DE3). The expressed protein was found to be functional and 
retained an order-packed structure. From the experimental data, Glu84 and Asp85 of 
UGT1A8 were shown to play an important role in the ligand coupling. Also, Trp208 
was shown to play a role in proper folding of the protein. Besides, those amino acid 
residues that were suspected to take part in ligand binding were probed out by 
computer modeling. 
The present study showed that UGT1A8 shares a high homology of amino acid 
sequences and structure with other family members, and provides useful information 
on the structure-function relationship of the enzyme. It enables us to get some insights 


























Chapter 1 Introduction 
1.1 Drug Metabolism 
Metabolism is derived from Greek word for "change" or "overthrow". It means the 
modification of chemical substances in living organism by biochemical reactions. 
Metabolic reactions of organic compounds are divided into two types, i.e. anabolic 
(building up) and catabolic (breaking down). All metabolic reactions are involved of 
enzymes and the presences of these biological catalyses are important for the proper 
functions in sufficient rate. 
Drug metabolism is the metabolic reactions of drug. It is mainly catabolic or 
modification, through specialized enzymatic systems. Most of the drug metabolisms 
aim to convert hydrophobic chemical compounds into more polar and hydrophilic 
products for limiting the distribution inside the body and easier excretion through 
urine. 
Most drug metabolic reactions are carried out in the liver. As liver is the first organ 
where the substances absorbed by the guts will be reached, it acts a very important 
role as the first-pass effect. Liver contains very high concentrations of drug metabolic 
enzymes and other sites of drug metabolism include epithelial cells of the 
gastrointestinal tract, lungs, kidneys, and the skin. These sites are usually responsible 
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for localized toxicity reactions. 
Almost all drugs are xenobiotics, which mean they are not normally present in the 
body and should be taken in from the environment. 
In human, the drug metabolic reactions are included of two phases, i.e. phase I and 
phase II, and different enzymes set are involved (1). 
Phase I reactions may include the oxidation, reduction or hydrolysis of the drugs. 
After the reactions, the chemicals will become more hydrophilic due to the addition or 
exposing of polar groups of the metabolites. In some cases, the products will be 
excreted from the body if they are soluble enough. However, in most cases, the 
products of phase I reactions need to be further processed and will act as substrates of 
the phase II reactions. 
Enzyme systems involved in the oxidation phase I reaction are cytochrome P450 
monooxygenase system, flavin-containing monooxygenase system, alcohol 
dehydrogenase, aldehyde dehydrogenase, monoamine oxidase and peroxidases. Also 
NADPH-cytochrome P450 reductase and reduced ferrous cytochrome P450 take part 
in the reduction of chemicals. Besides that, epoxide hydrolase, esterases and amidases 
are responsible for the hydrolysis of the metabolites. 
Phase II reactions are mainly involved the interaction of the polar functional groups 
and conjugation of the metabolites with some groups from other co-substrates. 
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Enzymes which belong to phase II reactions include the glutathione 
S-transferases(GST), UDP-glucoronosyltransferases (UGT), N-Acetyltransferases, 
amino acid N-acyl transferases and sulfotransferases. 
After the phase II detoxification steps, most metabolites will be hydrophilic enough 
and to be excreted in urine (2). 
1.2 Glucuronidation 
Glucuronidation is an important metabolic pathway to convert many xenobiotic and 
endobiotic to more hydrophilic form, so the chemicals are easier to be excreted and 
can also limit the distribution inside the body and reduce the biological activities. 
Glucuronidation uses UDP-glucuronic acid (UDPGA), structure shown in Figure 1.1, 
a chemical that the uridine 5 -diphosphate is linked to the glucuronic acid via a 
glycosidic bond, as a co-substrate (3). 
“r^ ^X I I 3 . � 0 o 
O—R I 
OH OH 
Figure 1.1. The structure of UDP-glucuronic acid. 
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When both the UDPGA and the alycone substrate are present together with 
UDP-glucuronosyltransferases (UGTs), glucuronidation will occur (Figure 1.2). 
Glucuronidation is a Sn2 substitution process in which the CI atom of the glucuronic 
acid is attacked by the nucleophilic heterostom of the aglycone (4). The Sn2 reaction 
is supported by inversion of the a -configuration of the C1 atom to /5 -configuration 
in the glucuronide and also the substituent effects on the glucuronidation rate. The 
UDP-glucuronic acid is synthesized in the liver (5). 
The UDP-glucuronosyltransferases is responsible for catalyzing glucuronidation (6). 
UGTs are located on the luminal side of the endoplasmic reticulum and also the 
nuclear envelop of liver and other organs' cells (7). It catalyses the transfer of 
glucuronic acid from the co-substrate uridine 5 -diphosphatea-D-glucuronic acid 
(UDPGA) to the substrate, in which the substrate can be xenobiotic and endobiotic 
compounds like drugs. 
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Figure 1.2. The UGT catalyzes the glucuronidation reaction. 
1.3 UDP-glucuronosyltransferases (UGTs) 
1.3. INomenclature 
In 1997, Mackenzie recommended to define the UDP-glycosyltransferases as UGTs， 
but not UDP-glucuronosyltransferases (8). The grouping is based on limited sequence 
homology and the presence of a predicted UDP-glucosyltransferase signature 
sequences. Upon these criteria, over 50 well-characterized and endoplasmic reticulum 
localized UGTs, several vertebrate UDP-sugar acceptor proteins and many 
invertebrate proteins that are not characterized are grouped into the same family. 
However, this nomenclature system shows several problems in precise description of 
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the well-characterized UGTs. When the evolutionary relatedness is based on similarity 
of amino acid sequences, it is possible that some important UTP-sugar accepting 
proteins may be excluded. Also, many nonvertebrate-related 
UDP-glycosyltransferases are distantly related to the UGTs. There are no 
experimental evidence showing that they can utilize glucuronic acid as a cosubstrate. 
In order to overcome these drawbacks, an improved nomenclature system is proposed 
by Strassburg (9). With reference to the case of P450 family (10), only those proteins 
with more than 40% amino acid sequence homology will be grouped into the UGT 
superfamily. The members of the superfamily are refined into several families, like 
UGTIA, UGT2A, when their protein sequences share at least 55% homology. After 
the proteins are grouped into families, this is still not the end of the classification. The 
members in the same family are further divided into subfamilies based upon 
predictions of phylogenetic divergence and share 60% homology (Figure 1.3). 
The most important criteria of the nomenclature system is that the proteins should 
utilize UDP-glucuronic acid as co-substrate. 
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Figure 1.3. Phylogenetic tree of the 18 human UDP-glucuronosyltransferases (UGTs). 
The UGT proteins have been categorized into two families, UGTl and UGT2, with 
UGT2 being subdivided into two subfamilies, UGT2A and UGT2B. Amino acid 
sequences of human UGTl A and UGT2B enzymes were from the GenBank database. 
UGT1A2, UGTl A l l , UGT1A12 and UGT1A13 are pseudogenes. The human 
UGT2B enzymes isolated to date are named according to their chronological order of 
isolation. Five human UGT2B pseudogenes have also been isolated, whereas 16 
UGT2B enzymes have been characterized in rats, monkeys and rabbits. 
1.3.2 Tissue Distributions of UGTs 
Tissue distribution in human 
The expression profiles of UGTl As vary in different tissues and are tissue specific 
(Figure 1.4). In human liver, UGTlAl, UGT1A3, UGT1A4, UGT1A6 and UGT1A9 
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mRNA are expressed (11). However, UGTl AlO is present in all tissues of the 
gastrointestinal tract except liver (9, 11, 12, 13, 14). The expression of UGTl A locus 
in colon is most diverged, with the mRNAs of UGTl Al, UGTl A3, UGT1A4, 
UGT1A6, UGT1A8, UGT1A9 and UGTl AlO are detected (11). The distribution 
patterns of UGTs in different tissues show the important roles of other extrahepatic 
organs on detoxification, for example the UGTl AlO is the enzyme that has the widest 
range of substrate specificities when compared with other UGTs and it can 
glucuronidate substrates from small phenolics to steroids. However this enzyme is not 
expressed in the liver but in other tissues (9). This expression profile can be explained 
on the first contact of xenobiotics with the surface epithelia of the gastrointestinal 
tract and respiratory system prior to the absorption in the body. 
UGT2 family is considered to play a major role in the steroid-like ligand 
glucuronidation, even the metabolisms of steroid are very diversified indeed (9, 
15-25). Similar to that of UGTl A locus, the expression pattern of the UGT2 locus is 
tissue-specifc. As a result of their functions in steroid metabolism, UGT2B locus 
genes are found to be expressed abundantly in steroid-sensitive organs like prostate 
and mammary gland. UGT2A1, one of the most versatile members in the UGTs 
family, which can catalyze all of the major class of substrates, is expressed only in the 
olfactory tissue. The specific expression of UGT2A1 may be caused by similar 
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activities for UGTl A10, i.e. the first contact of the xenobiotics as the detoxification 
processes in the nasal mucosa can serve as the first line of defense (26). In human 
liver, the UGT2 gene cluster express UGT2B4, UGT2B7, UGT2B10, UGT2B11 and 
UGT2B15 (9, 20,21,27-30). 
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Figure 1.4. Expression of human UDP-glucuronosyltransferases (UGTs) mRNA in the 
human body (9). 
Tissue distribution in rat 
In rat, the UGTs family shares the same classification as that of human. The UGTs are 
divided into 3 subfamilies, i.e. UGTl A, UGT2A and UGT2B. 
The UGTl A gene cluster express ftmctional UGTlAl , UGT1A2, UGTl A3，UGT1A5, 
UGT1A6, UGT1A7 and UGT1A8 (Figure 1.5), while UGT1A4 and UGT1A9 are 
pseudogenes (31). 
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Figure 1.5. Expression levels ofmRNAs of UGTlAl, UGT1A2, UGT1A3, UGT1A5, 
UGT1A6, UGT1A7 and UGT1A8 in different male and female rat tissues 
(n=4-5/gender). The level is scaled as Relative Light Unit/5ug of total RNA (32). 
For UGT2 family, the expression pattern of UGT2A1 is similar to that of human. The 
protein is expressed in olfactory tissue (Figure 1.6). 
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Figure 1.6. mRNA expression level of UGT2A1 in different tissues of male and 
female rats (9). 
The names of UGT2B family members are based on the order they are cloned (32, 33). 
UGT2B1, UGT2B2, UGT2B3, UGT2B6, UGT2B8 and UGT2B12 are expressed in 
rat gene locus (Figure 1.7). 
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Firgure 1.7. Expression levels ofmRNAs of UGT2B6, UGT2B8, UGT2B12, 
UGT2B1, UGT2B2 and UGT2B3 in different male and female rat tissues 
(n=4-5/gender). The level is scaled as PLUs/5ug of total RNA (32). 
As we can see from the mRNA level of UGTs, the expression of the proteins are 
tissue-specific, same as human. The expression profiles of many UGTs are very 
similar among rat and human, for example almost all tissues express UGTl Al, 
UGT1A7 are expressed in many organs of gastrointestinal tract but not in liver. Also 
the specific expression of UGT2A1 in olfactory tissue appears in human also. 
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1.3.3 Genetics 
Up to date there are more than 60 UGT isoenzymes that have been identified in 
several mammalian species (9, 34, 35). Based on their sequence similarity, they can 
be divided into two major families, UGTl and UGT2 (9). The UGT2 family is further 
sub grouped into 2A and 2B with the different in their gene structure and tissue 
distribution (36). When further look into the 1A family, it reveals two distinct clusters 
based on sequence similarity. In human the cluster B subgroup includes functional 
UGT1A7 (12, 40)，UGT1A8 (13, 37, 38, 40)，UGT1A9 (39) and UGTl AlO (11, 12, 
14) and three pseudogenes lAl 1, 1A12 and 1A13. While in rat, there are three 
proteins in this cluster, i.e. UGT1A7, UGT1A8 and UGTl AlO. 
In human the UGTl locus (41) is located on the chromosome 2 location q37 (42, 43, 
44), while the rat UDP-glucuronosyltransferase 1 family locates on the chromosome 9 
(NCBI Genome ID: NC_005108) location q35-q36 (45) with RATMAP ID 34521 and 
LocusID is 24861 (Figure 1.8). 
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Figure 1.8. Genome context of rat chromosome 9 with location 9q35-q36. 
The UGTl family is different from the UGT2 based on the gene arrangement. The 
members of UGT2 family are encoded by several unique genes (32, 36). However, in 
the UGTl family, the members are transcribed from a complex gene based on a 
multiple variable first exon and exons sharing mechanism (31, 40, 41). The gene 
contains 17 exons and all isoenzymes are transcribed by 13 alternative splicings of 
different exon 1. The 3 -donor slicing site of the first exon are spliced to the acceptor 
site of exon 2, resulting in joining with exon 2 to 5 which are common among all 
members. Each UGTl A gene has their only TATA-like elements upstream and their 
transcription regulatory is independent from others. As a result of this gene 
arrangement, all UGTl A family members vary in the first exon primary structure (9). 
Due to sharing of common exons, polymorphisms in these regions which lead to 
decrease or loss of function can cause several diseases with varying degree of 
hyperbilirubinemia. The diseases include relatively harmless Gilbert's or 
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Figure 1.9. Organization of the human and rat UDP-glucuronosyltransferase-1 gene 
locus. 
Figure 1.9 shows the arrangement of gene which encode the UGTl A family in human 
and rat. The members share consistent C-terminal sequences (exons 2 to 5) but with 
various N-terminal primary structure (exon 1). The arrow in the figure shows the 
direction of gene transcription and "P" represents the gene is a pseduogene. 
1.3.4 Evolution of UGTs 
Apart from the difference in the exon 1 sequences, they share high homology between 
family members and even among different species, their similarity is still high. 
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Figure 1.10. UGTl locus arrangements of mouse, rat and human. 
We can see from the figure that the exons arrangements of UGTl locus in human, rat 
and mouse retain high similarity (Figure 1.10). When investigating the organizations 
between mouse, rat and human, they both share the cluster structure comprised of 
multiple, highly similar, tandem variable exons followed by one set of constant exons 
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(1 to 4). Exons in variable regions are indicated by colored boxes regarding to their 
substrate specificity: (green) phenol-type UGTl variable exons; (orange) 
bilirubin-type UGTl variable exons; (blue) pseudogenes or relics (present in both 
Pcdh and UGTl clusters); (turquoise) non-UGTl genes in the UGTl cluster; (pink) 
constant exons (present in both Pcdh and UGTl clusters). 
This kind of similar locus is also found in many mammals like rabbit, dog etc. It is 
believed that the gene is present since the early age of Paleocene, i.e. around 65 
million years ago and at that time humans, rodents and many other mammals are still 
not diverged yet (46). 
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Figure l . l l . The Neighbor joining tree of UGTs. 
The Neighbor joining tree (Figure 1.11) shows the evolution patterns and 
relationships between several mammals. The neighbor-joining method is a special 
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case of the star decomposition method. In contrast to cluster analysis neighbor-joining 
keeps track of nodes on a tree rather than taxa or clusters of taxa. The raw data are 
provided as a distance matrix and the initial tree is a star tree. We can see the UGT 
origin gene was diverged into family UGTl, UGT2 and UGTS. Afterwards, the UGTl 
gene is further evolved into lA and IB. 
The original UGT function is detoxification of polyphenolic phytoalexins and 
degradation of phytoestrogens of plants by plant-feeding animals. This prey and 
predator relationship in the nature drives the generation and evolution of UGTl locus 
(48, 49). The hypothesis can be shown in the evolution pattern of UGT1A6. This 
enzyme is responsible for glucoronodation of small phenolic substrates like 
4-nitrophenol and 1-napthol. In herbivorous lagomorphs (rabbit), the UGT1A6 genes 
clusters are duplicated and resulted in up to six rabbit UGTl A6 genes (47). These 
genes were characterized and showed that their protein products retain a 98% 
homology. This duplication is unique for rabbit. In human and rodents, there is only 
one gene fragment in their genome. In some carnivorous animals like cats, their 
UGT1A6 was found to be pseudogenes (50). This evolution trend can be explained as 
the feeding pattern of the animals. Rabbits which feed only on plants need to handle 
lots of phytochemicals and their detoxifying enzymes are evolved and diverged into 
many isoenzymes. However, in carnivorous animals, they feed on herbivorous or 
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other carnivorous animals which have done the job of detoxifying phytoalexins 
resulting in fewer variations in their enzyme genes and even some of them come to 
the dead end of the evolution, i.e. they become pseudogenes. 
1.4 UDP-glucuronosyltransferase related Human Diseases 
1.4.1 Hyperbilirubinemia 
Hyperbilirubinemia is also known as icterus and jaundice. The patient will have their 
skin, sclera and mucous become yellow in color. This disease is caused by high 
bilirubin level in serum. When the level of bilirubin is higher than 35 uM/L of serum 
(51), the patient is diagnosed to suffer from jaundice. Bilirubin is an endogenous 
substance that generated from the break down processes of heme-containing proteins, 
in which 80% come from hemoglobin of red blood cells and other hepatic 
heme-containing proteins like cytochrome P450s, tryptophan pyrrolase and catalase, 
and also free hemes the body account for the remaining 20% (9). 
There are three causes of hyperbilirubinemia, i.e. pre-hepatic (52), hepatic and 
post-hepatic (52). Pre-hepatic hyperbilirubinemia is caused by the increase in the 
production of bilirubin and mainly caused by the raised rate of red blood cells 
breakdown processes. It can also be caused by the decrease in the rate of bilirubin 
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removal. Diseases like malaria and sickle cell anemia, and genetic defects. 
Hepatic hyperbilirubinemia is induced by the reduction or loss of liver functions, 
resulting in reduced rate of bilirubin metabolic rate, Crigler-Najjar syndrome types I 
and II. Gilbert's syndrome belongs to this class of causes. 
The third cause is cholestasis, in which the drainage of bile in biliary system is 
interrupted, like the presence of gallstones (53). 
As UGTs are important phase II detoxifying enzymes and take part in the metabolism 
of bilirubin, polymorphisms in the UGT gene locus can lead to hyperbilirubinemia 
(41, 54). As mentioned before, human UGTl A locus contains nine functional UGT 
genes, only UGTl A1 gene is known to be responsible for hyperbilirubinemia (55). It 
is because UGTl A1 is the only enzyme that can catalyze the glucuronidation of 
bilirubin. Although there is low activity of UGTl A4 towards bilirubin, the effect is 
not biological significance (54). There is no substitute enzyme for it if the function of 
UGTl A1 is lost or reduced. Hyperbilirubinemia can be caused by the mutation in 
N-terminal region (56, 57-62), C-terminal region (58, 67-75) and the transcription 
control elements of the UGTl A1 gene (64，65, 66). The degree of seriousness 
depends on the impacts of these mutations on the transcription level and activity of 
the proteins. Inherited unconjugated hyperbilirubinemia includes Crigler-Najjar 
syndrome type I, Crigler-Najjar syndrome type II and Gilbert's syndrome. 
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. _ _ Erkzvnie <)ctivrtv 
Allele nu�tvMni$| Pi oteii^  IJucieoti^ le Change Atrkimo Aci<l Exon Effect 1  
in vivo in v i t r o 
UOT1A1 UOT1A1 .1 Wild-type 
UGT1A1 *2 UGT1 A l .2 879del13 Frameshift 2 Frameshift CN1 Absent Absent 
UGT1A”3 UGT1A1 .3 1124CC>T) s^^^F 4 CN1 Inactive Inactive 
UGT1A1 UGT1 A l 4 1069�C>T) 3 CN1 Inactive Inactive 
UGT1A1 UGT1A1 .5 991 CC>T) 2 Exon 2 deletion CN1 Absent Inactive 
UGTl A l UGTl A l .6 211 CO>A.J G71R 1 Reduced Reduced 
UGT1 A l *7 UGT1A1 .7 1456CT>G) Y486D 5 CN2 Reduced Reduced 
UGT1A1 UGT1A1 .8 625�C>T� R209W 1 CN2 4 4% Reduced 
UGT1A”9 UGT1A1 9 992CA>G) 0331R 2 CN2 Reduced Reduced 
UGT1A1 0 UGTl A1 10 1021 CC>T) R341 X 3 CN1 Absent Absent 
UGT1 A l 1 UGT1A1 .11 923CG^A) G308E 2 CN1 Absent Absent 
UGT1A1 2 UGT1 A l .12 524CT>A) LI 75Q 1 CN2 38 4% Reduced 
UGT1A1 3 UGT1A1 .13 508del3 70del 1 CN1 Inactive Inactive 
UGT1A1 4 UGT1A1 .14 826CG>C) G276R 1 CM1 Inactive Inactive 
UGT1A1 UGT1A1 15 S29�T>C) C177R 1 CN1 Inactive Inactive 
UOT1 A l 6 UGT1 A l .16 1070CA>0) Q357R 3 CN1 Absent Absent 
UGT1A1 7 UGT1 A l 17 1143�C>G) S381R 4 CN1 Absent Absent 
UGTl A1*18 UGT1A1 .18 1201 CG^C) A401P 4 CN1 Absent Absent 
UGT1A1 9 UGTl A l .13 1005� i3>A� W335X 3 CN1 Absent Absent 
UOT1A1 UGT1A1 20 1102CG^A) A368T 4 CN1 Absent Absent 
U G T l A 1 *20 U G T 1 A 1 .20 1 1 0 2 ( G > A ) A 3 6 8 T 4 CN1 A b s e n t A b s e n t 
U G T l A 1 *21 U G T 1 A 1 .21 1 2 2 3 i n s G F r a m e s h i f t 4 F r a m e s h i f t CN1 A b s e n t A b s e n t 
U G T 1 A 1 *22 U G T 1 A 1 .22 8 7 2 � C > T ) A 2 9 1 V 2 CN1 A b s e n t A b s e n t 
U G T 1 A 1 *23 U G T 1 A 1 . 2 3 1 2 8 2 ( A > G � K 4 2 6 E 4 CN1 A b s e n t A b s e n t 
U G T 1 A 1 *24 U G T 1 A 1 . 2 4 1309C A > T ) K 4 3 7 X 5 CN1 A b s e n t A b s e n t 
U G T 1 A 1 *25 UGT1 A l .25 8 4 0 � O A � C 2 8 0 X 1 CN1 A b s e n t A b s e n t 
U G T 1 A 1 * 2 6 U G T 1 A 1 .26 9 7 3 d e l G F r a m e s h i f t 2 F r a m e s h i f t C N 2 A b s e n t A b s e n t 
U G T 1 A 1 *27 U G T l A 1 .27 6 8 6 C C > A ) P 2 2 9 Q 1 Gi lbert R e d u c e d R e d u c e d 
U G T 1 A 1 *26 U G T 1 A 1 .28 A C T A ) 6 T A A t o A C T A ) 7 T A A Promote r Gi lber t R e d u c e d R e d u c e d 
U G T 1 A 1 * 2 9 U G T 1 A 1 .29 1 0 9 9 ( C > G ) R 3 6 7 G 4 Gi lbert R e d u c e d R e d u c e d 
U G T 1 A 1 * 3 0 U G T 1 A 1 .30 4 4 � T > G ) L I 5R 1 CN2 R e d u c e d R e d u c e d 
U G T 1 A 1 ' 3 1 U G T 1 A 1 .31 1 1 6 0 � C C > G T � P 3 8 7 R 4 CN1 A b s e n t Atoserrt: 
U G T 1 A 1 *32 UGT1 A l .32 1 0 0 8 C A > T ) R 3 3 6 W 3 CN1 0 - 1 0 % A b s e n t 
U G T 1 A 1 * 3 3 U G T 1 A 1 .33 881 CT>C) I294T 2 CN2 4 0 - 5 5 % 
U G T l A l * 3 4 U G T 1 A 1 . 3 4 9 2 9 ( A > G � M 3 1 O V 2 CN2 2 6 % - 5 1 % 
UGT1 UGT1 A l .35 1291CT>C) 1431T 4 C N 2 61 % - 8 1 % 
U G T l A 1 * 3 6 U G T 1 A 1 .36 A ( T A ) 6 T A A t o A ( T A ) 5 T A A Promote r I n c r e s s e d I n c r e a s e d 
U G T l A 1 *37 U G T 1 A 1 . 3 7 A ( T A � 6 T A A t o A ( T A ) 8 T A A Promote r CM2 R e d u c e d R e d u c e d 
U G T 1 A 1 * 3 8 U G T 1 A 1 .38 991 ( C > T ) Q 3 3 1 X 2 CN2 
U G T 1 A 1 * 3 9 U G T 1 A 1 .39 1 2 0 1 CG>C)>1308(A>T) A 4 0 1 P / K 4 3 7 X 4; 5 CN1 
U G T 1 A 1 * 4 0 U G T 1 A 1 .40 8 7 2 C C > T ) / 1 2 8 2 � A > < 3 � A 2 9 1 VA<426E 2: 4 CN1 
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U G T 1 A 1 * 4 1 U G T 1 A 1 4 1 1 2 0 - 1 2 1 d e l C T F r a m e s h i f t 1 F r a m e s h i t t C N 1 
U O T 1 A 1 M 2 U O T 1 A 1 . 4 2 1 3 9 1 A C T A ) 7 T A A E 4 6 4 A 5 C N 2 
U G T 1 A 1 U G T l A 1 . 4 3 6 9 8 C A > C ) ' - 2 3 3 A 1 -
U G T 1 A 1 M 4 U G T 1 A 1 . 4 4 1 1 5 ( C > < 3 ) H 3 9 D 1 C N 1 
U O T 1 A 1 M S U O T 1 A 1 . 4 5 2 2 2 C C > A 〕 Y 7 4 X 1 C N 1 
U G T l A 1 * 4 6 U O T 1 A 1 . 4 6 5 1 7 d e l C F r a m e s h i f t 1 F r a m e s h i t t C N 1 
U G T 1 A 1 * 4 7 U G T 1 A 1 . 4 7 7 2 2 - 7 2 3 d e l A G F r a m e s h i f t 1 F r a m e s h i f t C N 1 
L J G T 1 A ” 4 8 U O T 1 A 1 4 8 6 7 1 ( T = > 0 ) > 7 2 2 - 7 2 3 d e l A G V 2 2 4 G / F r a m e s h i f t 1 F r a m e s h i f t C N 2 
U O T 1 A 1 * 4 9 U G T 1 A 1 . 4 9 1 0 4 6 d e l A F r a m e s h i f t 3 F r a m e s h i f t C N 1 
U O T 1 A 1 * 5 0 U O T 1 A 1 S O 1 2 2 3 d e l A > N F r a m e s h i f t >TvJ 4 F r a m e s h i f t C M 1 
U G T 1 A 1 - 5 1 U G T 1 A 1 .51 1 1 3 O ( A > G 0 则 H377RyTvJ 4 CN2 
U G T l A 1 « 5 2 U O T 1 A 1 . 5 2 1 1 3 3 ( O ^ T ) G 3 7 7 V 4 CN2 
U G T 1 A 1 U G T 1 A 1 . 5 3 1 4 5 1 ( O ^ A ) W 4 8 4 X 5 C N 1 
U O T 1 A 1 * 5 4 U O T 1 A 1 . 5 4 1 4 5 2 i : 0 > A ) W 4 8 4 X 5 C N 1 
U G T 1 A 1 U O T 1 A 1 . 5 5 1 4 9 0 C T > A ) / N L 4 9 7 X > N 5 C N 1 
U G T 1 A 1 * 5 6 U G T 1 A 1 . 5 6 S p l i c e a c c e p t o r s i t e I n t r o n 1 I r r t ron 1 C N 1 
U O T 1 A 1 * 5 7 U O T 1 A 1 . 5 7 S p l i c e d o n o r site I n t r o n 3 I n t r o n 3 C N 1 
U O T 1 A 1 * 5 8 U O T 1 A 1 . 5 8 1 4 5 C C > T ) Gl49X 1 CN1 
U G T 1 A 1 * 5 9 U O T 1 A 1 . 5 9 1 1 8 6 d e l O F r a m e s h i f t 4 F r a m e s h i f t C N 2 
U G T 1 A 1 « 6 0 U O T 1 A 1 . 6 0 - 3 2 6 3 C T > 0 ) P r o m o t e r G i l b e r t 
U O T 1 A 1 * 61 U O T 1 A 1 .61 S p l i c e d o n o r s i t e ( O A ) I r r t ron 3 I n t r o n 3 C N 1 
UGT1 A1 *62 UGTl A1 .62 247(T>C〕 F83L 1 Gilbert 
UGT1 A1 *63 UOT1A1 .63 877CT>A)/878-890del Frameshift/De 丨 2 Frameshift CN1 
UOT1 A1'=64 UOT1 A1 .64 1 21 SCA^G：)/ ACTA)6TAA to ACTA)8TAA N400D 4 CN2 
Table 1.1. Different alleles of UGTl A1 gene. The nucleotide and amino acid changes 
are shown in the table. Alleles that are responsible for Crigler-Najjar syndrome type I 
(CNl) , Crigler-Najjar syndrome type II (CNII) and Gilbert's syndrome also shown (9, 
60, 66). 
As we can see from the Table 1.1, there are 60 alleles of UGTl A1 that can cause 
hyperbilirubinemia. Complete loss of bilirubin glucuronidation is due to the 
homozygous mutation in exon 1, and it leads to Crigler-Najjar syndrome type I. 
Crigler-Najjar syndrome type II，which is characterized by the low amount of 
bilirubin diglucuronides and monoglucuronides is caused by reduced activity of 
U G T l A l and the rate can be as low as 10% of the normal activity. The Gilbert's 
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syndrome is the least serious case of inherited hyperbilirubinemia (63). The UGT 
activity retained 60 to 70 % of the normal activity and most young patients do not 
require receiving treatment. 
1.4.2 Cancer 
Chemical carcinogenesis is one of the major causes of tumor formation. Lung, liver, 
stomach, colon cancers are often induced by carcinogen. Carcinogens can be both 
xenobiotic or endobiotic chemicals, like steroid produced in the body and 
benzo(a)pyrene from the pollutants. As UGTs are key factors in detoxification, 
glucuronidation is often needed for excretion of metabolic products. It is believed that 
malfunction of UGTs should play a role in cancer formation (76, 77’ 78). 
In Gunn rat animal model, the incapable expression of genes in UGTl A locus due to a 
mutation resulted in a dramatic reduction in benzo(a)pyrene glucuronidation (79). As 
a result, the level of DNA adducts increases and raises the risk of tumor formation 
(80). 
In human, down-regulated UGTl A mRNA expression and catalytic activity of UGTs 
are found in gastrointestinal tumors like esophagus, stomach, liver and bile ducts 
cancers. 
Many environmental mutagens were found to be substrates of UGTs. Primray amines 
are glucuronidated by UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9 and 
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UGT2A1 and several derivatives of benzo(a)pyrenes are substrates of UGTl A6, 
UGT1A7, UGT1A8, UGT1A9, UGTIAIO and UGT2B7 (9). The capability of UGTs 
to glucuronidate and promote the excretion of these chemical mutagens suggests that 
the enzymes are important in the protection of organisms from carcinogenesis. 
1.5 Rattus norvegicus UDP-glucuronosyltransferase 1A8 
The human UDP-glucuronosyltransferase 1A8 (UGT1A8) isoform is first discovered 
by Strassburg's broup in 1998 (13). In 2002, our research group found the homolog of 
human UGT1A8 in Sprague-Dawley rat (81). As the gene sequence of rat UGTl A8 is 
highly homologous to that of human (with homology around 80%), it is often used as 
a model to study the protein of human (Figure 1.12). 
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Figure 1.12. This figure shows the relative order and sequence identities of UGTs 
encoded by rat and human UGTl A7-like forms. The dark boxes indicate the exons 
and the homology of N-terminal sequences between different genes are represented in 
percentage (40). 
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The gene locus codes for a mRNA with 2241 nucleotide base pairs and after mRNA 
splicing, the cDNA of rat UGT1A8 contains 1593 nucleotide base pair. The protein 
product has 530 amino acids (Figure 1.13) with the molecular weight of 60083 Da. 











Figure 1.13 . The amino acid sequence of rat UDP-glucuronosyltransferase in FASTA 
format obtained from the ExPASy protein database ( ref. no.:Q8VD44). 
The protein sequence of rat UGTl A8 is shown in Fig 14. For these 540 amino acids, 
the first 294 amino acids are encoded by exonl and the remaining 246 amino acids at 
the C-terminal end are encoded by exon2 to 4, which are conserved among UGTl A 
family members. 
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Figure 1.14. The mRNA expression levels of rat UGTl A7 and UGTl A8 in different 
male (black box) and female (grey box) rat tissues. The expression level is scaled as 
each relative light unit equals to 5ug of RNA (13). 
The average expression levels of other UGTs are found to exceed 20 relative light 
units and the expression of UGTl A8 is relatively very low. Each relative light unit is 
equivalent to 5ug of RNA. Even the liver has the highest UGTl A8 mRNA detection 
level, it is less than 15ug of RNA (3 relative light units) of UGTl A8 to be measured 
(Figure 1.14). This low expression level of UGTl A8 makes the protein very difficult 
to be discovered and that is the reason why it is first detected in 2002, whereas other 
UGTs have been studied for more than a decade. The expression pattern of the protein 
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shows sex-dependent manner in which the level of female rat is significantly higher 
than that of male rat. 
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Table 1.2. The activities of UGTl A8 towards different substrates. N.D. represents 
there is no detectable activity (40). 
Rat UGT1A8 catalyses several BaP substrates with high activity like 1-OH, 4-OH and 
5-OH derivatives of phenol (Table 1.2). However, when compared with other UGTs 
like UGT1A7 or UGTl Al, the specificity of UGTl A8 is more restricted. Effective 
substrates of UGTl A8 share a common superimposable 1-napthol structure and the 
absence of this structure would reduce the activity (40). Also the substrates share a 
common feature in that the substrate is planar with less bulky side chain. These strict 
requirements of the UGT1A8 results in fewer substrates that can fit into the binding 
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domain. 
1.6 Aims of the project 
In the project, the structure of rat UGTl A8 was investigated. Mutagenesis and 
computer modeling were done to study the structure-function relationship as detailed 
information on UGTs are lacking. The high homology of rat UGTl A8 between that of 
human and other UGTs makes it a good model for the study. 
The recombinant expression of the protein in E.coli can lead to quantitative 
production of the protein with high homology and chromatography makes the 
purification easier. Circular dichorism and chemical denaturation studies would 
provide information on the structure of the protein while the modeling and 
site-directed mutagenesis can help us to probe the possible binding pocket of the 
ligand. With these studies, we can know more about the working mechanism behind 
the UGTs and help to identify possible polymorphism site which can affect the 
function of UGTs that may cause illness to patient by locating those residues essential 
for glucuronidation. 
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Chapter 2 Materials and Methods 
2.1 Materials 
1. Rat liver mRNA Extraction 
The mRNA was extracted from male Sprague-Dawley (SD) rat in the Animal House 
of the Chinese University of Hong Kong. The Trizol reagent was purchased from 
Invitrogen. The ethanol and isopropanol in analytical grade were purchased from 
BDH and the water used in the experiment was sterilized by autoclaving after addition 
of 0.5% diethylpyrocarbonate (DEPC, from Sigma) and mixing for overnight. 
2. RT-PCR of rat liver mRNA 
The M-MULV reverse-transcriptase and reaction buffer were purchased from 
Amersham Biosciences and the oligo (dT) primer was bought from Invitrogen. 
3. Amplification of UGTl A8 gene from the cDNA library 
Pfu DNA polymerase and reaction buffer (with 25mM Mg) (Promega) was used in the 
reaction and dNTP was the product of Portman. Amplification primers were 
synthesized by Proligo in the scale of 5 O.D. Band detection in DNA gel was done by 
BioRad Gel Dock system. The target band was cut out with an UVItec gel 
documentation system. Viogene Gel-M purification kit was used for PCR product 
purification from DNA gel. 
4. Construction of bacterial expression vector 
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The prokaryotic expression vector, pRSet B, was purchased from Invitrogen. 
Restriction enzymes, T4 DNA ligase and Calf Intestinal Alkaline Phosphatase (CIP) 
were products of New England Biolabs. Viogene Mini-M Plasmid Extraction Kit was 
used to extract plasmid from E.coli. 
5. Expression of recombinant protein in E.Coli 
BL21, JM109 and DNS a bacterial cell strains were produced from Novagen and they 
were grown in LB Medium (USB). The protein production was induced with IPTG 
(USB). 
6. Purification of protein with Ni column 
Ni resins were purchased from Novagen. Tris, EDTA, imidozole, sodium chloride and 
phenylmethyl sufonyl fluoride (PMSF) were bought from USB. 
7. Purification of protein with gel filtration column 
A K T A t m f p l c t m chromatography system with fraction collector Fc-950 and the 
column used, HiLoacpM Superdex 200 Prep Grade column were purchased from 
Amersham Biosciences. 
8. Sodium dodecyl sulfate poiyacryiamide gel electrophoresis (SDS-PAGE) 
BioRad Mini-PROTEAN system was used for electrophoresis. Chemicals in 
SDS-PAGE sample buffer (125 mM Tris-HCl, pH6.8，1 %w/v SDS, 5 %v/v glycerol, 
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10 mM dithiotheritol) were purchased from Sigma. BENCHMARK™ Protein marker 
from Invitrogen was used. Coomassie brilliant blue R-250 was a product of 
Boehringer Mannheimin. Ethanol and acetic acid were bought from Merck. 
9. Concentration and Desalting of protein 
Vivapore Static Concentrators from Sartorius were used to adjust the sample to the 
desired volume and 5 ml Desalting Columns from Amersham Biosciences were used 
for salt removal. 
10. Enzyme activity assay of glucuronidation 
1-napthol and UDP-glucuronic acid were purchased from Sigma. Tris, magnesium 
chloride were purchased from USB. A Perkin Elmer Model LS50B fluorescence 
spectrometer was used to measure the emission and excitation wavelength of the 
substrate. 
11. Near UV and far UV circular dichroism (CD) spectroscopy 
The curvette used in the experiment was purchased from Hellma and the CD 
spectroscopy was manufactured by Jasco with model number J-720. 
12. Fluorescence properties studies 
The intrinsic fluorescence, acrylamide quenching of intrinsic tryptophan and chemical 
denatumation studies of the protein were carried out with the fluorescence 
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spectrometer LS50B from Perkin Elmer. Guanidine chloride and other chemicals were 
purchased from USB. Polymethacrylate fluorimeter cuvettes were purchased from 
Sigma. 
13. Western Blotting 
The Western Blotting Advance Detection Kit was purchased from Amersham 
Biosciences and the nitrocellulose membrane was a product of Millipore. The film 
was product of Fujifilm. Primary antibody, Anti-Xpress, and secondary antibody were 
purchased from Invitrogen and Santa Cruz respectively. 
14. 3D modeling of UGTl A8 and interactions with ligands 
The modeling software used to build up the model was Insight II (Assclrys Software 
Inc.) on a UNIX platform and the system was running in a SGI workstation. Insight II 
can provide a powerful molecular modeling environment to study molecular dynamic, 
de novo design and electrostatics. With the assistance of different modules, Insight II 
can extend the functions to docking (with module DOCKING) and molecular 
dynamic and energy minimization studies (with module DISCOVER). 
2.2 Methods 
1. Rat liver mRNA extraction 
Rats were killed by nitrogen gas and dissected. The rat liver (500mg) was soaked into 
1ml Trizol reagent and homogenized. The homogenate was stored at room 
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temperature for 15 minutes to allow the lysis of cells. Then the homogenate was 
centrifuged at 12000g for 10 minutes at 4C. For separation of RNA, 0.2ml chloroform 
was added into the sample and mixed vigorously. Afterwards the sample was stored at 
room temperature for 15 minutes and centrifuged at 12,000g for 15 minutes at 4�C. 
After the RNA was separated, the upper aqueous layer, in which the RNA was 
dissolved, was transferred into a new tube and 0.5ml of isopropanol was added and 
mixed for the precipitation of RNA. The sample was allowed to stand for 15 minutes 
at room temperature and centrifuged for 12,000g for 15minutes at 4°C. When the 
centrifugation was finished, the RNA pellet was visible at the bottom of the tube. 
Then 1 ml 75% ethanol was added and mixed to wash the pellet. After that, the 
sample was centrifuged at 7500g for 5 minutes. The pellet, after washing, was 
air-dried and dissolved in 50ul of water. The RNA was stored in -20。C freezer. 
2. RT-PCR of rat liver mRNA 
The RNA concentration was determined by UV spectrometer with the measurement 
of light absorptions at 260nm and 280nm. The integrity and purity of extracted RNA 
was analysed by RNA gel. 
RNA (5ug) was used in the reverse transcription. The RNA was mixed with lug 
Oligo(dT) 12-18 and the reaction volume was added to 14ul with water. The mixture 
was heated to 70C for 10 minutes and then chilled on ice quickly. 
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After the mixture was ice-cooled, 4ul of 5X reaction buffer and lul of lOmM dNTP 
mix were added to give the reaction volume of 19ul. The mixture was mixed gently 
and incubated at 37。C for 2 minutes. After that lul of M-MLV Reverse Transcriptase 
was added and the reaction was allowed to run for 45 minutes at 37�C. The reaction 
was stopped by raising the temperature to 75°C for 10 minutes. 
3. Amplification of UGT1A8 gene from the cDNA library 
In an attempt to amplify the target gene from the cDNA of rat liver, the polymerase 
chain reaction (PCR) was performed. The sequences of the primers used in the 
reaction were listed below: 
• Forward primer 5 tttgccactaccttgatgagg3 
• Reverse Primer 5 gccaagcttgtccaaggagtggtaS 
The reaction mixture contained the following: 
1. 4ul 5X reaction buffer with 25mM Mg 
2. lul forward primer 
3. 1 ul reverse primer 
4. 0.4ul lOmM dNTP mix 
5. O.Sul cDNA 
6. O.Sul Pfu DNA polymerase 
Water was added to make the final reaction volume to 20ul. 
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The PCR was run as the protocol listed below. 
1. 94°C for 2 min 
2. 94°C for 30s 
3. 60°C for 30s 
4. 72°C for 4 min 
5. Repeat Step 2 to Step 4 for 25 cycles 
6. 72°C for 10 min 
7. 4�C forever 
After finishing the PCR, the mixture was loaded to 0.7% DNA agarose gel with 
0.05ug/ml of ethidium bromide and run it for 20 minutes with 130V. The target PCR 
product was visualized under BioRad Gel Dock system. The target band was cut 
under visualization with an UVItec gel documentation system and the product was 
purified using Viogene Gel-M purification kit according to the manufacturer's 
protocol. 
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4. Cloning of UGTl A8 PCR product into expression vector pRSet B 
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The purified PCR product and pRSet B vector were digested with Hindlll and BamHI. 
The reactions were left at 37�C for 2 hours and then heated at 75°C for 10 minutes to 
stop the reactions. The pRSet mixture was cooled down. Then 0.5ul of CIP was added 
and kept the reaction at 37�C for 1 hour. After the reaction was finished, the pRSet 
and UGTl A8 PCR product were loaded to DNA gel and purified with Viogene Gel-M 
purification kit. 
The UGT1A8 gene was inserted into the digested pRSet B vector by ligation. Ten 
units of insert were mixed with 1 unit of vector to a volume of 17.5ul. Then 2ul of 1 OX 
reaction buffer and 0.5ul T4 DNA ligase was added. The reaction mixture was 
incubated at room temperature overnight. 
The ligated product was added to lOOul DH5 a E.coli bacteria and placed on ice for 
40 minutes and heat shocked for 40 seconds. The bacteria was recovered by adding 
800ul LB medium and incubated for 1 hour at 37°C. After that the transformed 
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bacteria was spread on LB agar with lOOug/ml ampilicin and incubated at 37°C for 
18 hours. 
5. Confirmation of the presence of insert in the plasmid 
Cell colonies were picked and checked for existence of insert by colony PGR. 
The protocol of colony PCR was shown below: 
Reaction mix contained: 
• 2ul 1 OX reaction buffer 
• lul 25mM magnesium chloride 
• 0.5ul of T7 promoter sequencing primer 
• 0.5ul T7 reverse sequencing primer 
• 0.4ul dNTP mix 
• 0.2ul Taq DNA polymerase 
• water added to give the reaction volume to 20ul 
Run-down of PCR: 
1. 94�C for 2 min 
2. 94°C for 30s 
3. 55�C for 30s 
4. 72°C for 100s 
5. Repeat Step 2 to Step 4 for 30 cycles 
51 
6. 72�C for 10 min 
7. 4�C forever 
For those cell colonies with inserts, they grew in 10ml LB medium with lOOug/ml 
ampilicin. After 18 hours, the cells were harvested and the plasmids were extracted 
and purified using Viogene Mini-M plasmid extraction kit according to 
manufacturer's protocol. 
6. Sequence checking for UGT1A8 gene in the pRSet B vector 
The extracted and purified UGTlA8-pRSet B plasmid was sequenced with T7 and 
T7-reverse primers by the sequencing service provider Tech Dragon Ltd. 
7. Expression of recombinant protein in E.coli JM109 (BL21) cell strain 
JM109 (BL21) bacterial cell strain was prepared as lOOul aliquots and lul of 
UGTl A8-pRSet B plasmid was added to the bacteria and transformed into the cells, 
the transformed bacteria was spread on LB agar plate with lOOug/ml ampilicin and 
incubated overnight. 
Bacterial colony was picked and grown in 250ml LB medium with lOOug/ml 
ampilicin. The bacteria were incubated at 37�C with shaking at 250rpm. The 
production of recombinant protein was induced by adding 250ul of 1M IPTG when 
the OD600 of the bacterial reached 0.5. The bacteria were left for protein production 
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for 3 hours and then harvested by centrifuged at 6,000rpm for 10 minutes. 
8. Purification of recombinant protein by Ni-column 
The cell pellet was suspended in binding buffer (20mM, 0.5M NaCl and 5mM 
imidazole) and lysed by sonication at 2W output and 15 seconds time intervals for 15 
minutes. The lysate was centrifuged at 10,000g for 40 minutes to separate the soluble 
protein from insoluble cell debris. The supernatant was transferred to a new 15ml tube 
and mixed with Ni+resin. The mixture was kept in 4�C and rotated overnight so the 
protein could bind on the resin. The resin was loaded into a column and washed with 
10 volumes of binding buffer to remove unbound protein. After that, the column was 
washed with 5 volumes of washing buffer (20mM Tris, 0.5M NaCl and 60mM 
imidazole) to elute unspecific binding of other proteins. Lastly, the target protein was 
eluted with elution buffer (20mM Tris, 0.5M NaCl and IM imizadole) and collected 
in 1ml aliquots. 
9. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
The SDS-PAGE with 0.1% SDS was performed to analyze the elution profiles of the 
His-tag column. BioRad Mini-PROTEAN system was used for electrophoresis. 
Precipitated samples were incubated in SDS-PAGE sample buffer (125 mM Tris-HCl, 
pH6.8, 1 o/ow/v SDS, 5 %v/v glycerol, 10 mM dithiotheritol) at boiling temperature 
for 5 minutes. BENCHMARX^^ Protein marker was used. The gel was stained with 
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Coomassie brilliant blue R-250 in fixing solution of 30%v/v ethanol and 10 %v/v 
acetic acid for 30 minutes. Stained gel was destained in destining solution (30 %v/v 
ethanol, 10 %v/v acetic acid) till protein bands were visible. 
10. Recombinant protein purification by gel filtration column 
The protein collected in the eluted fraction was further purified with gel filtration 
colimn, HiLoad Superdex 200. The column was connected to the FPLC system and 
washed with 2 volumes (120nil) of water. Then two volumes of buffer (20mM Tris, 
0.5M NaCl, pH7.8) were run through the column. After that, the protein sample (1ml) 
was injected onto the FPLC system manually and the flow rate was set to Iml/min. 
One milliliter of each fraction was collected after the sample was injected. The buffer 
(2 volumes) was allowed to run and the elution profile was shown on the monitor. 
Fractions with target protein were collected (�6ml) . 
11. Concentration or Desalting of Purified Protein 
Solvent absorption concentrators were used to concentrate the purified protein to give 
a final volume of 1ml. Fractions collected after FPLC separation were loaded into the 
concentrator for concentration of samples. When the remaining volume was around 
1ml, it was transferred to a new tube. 
5ml desalting column was used to remove salt. The protein solution was loaded into a 
syringe and manually into the desalting column with 15 drops/min. The flow-through 
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was collected as 1 ml in each fraction. 
12. Determination of Protein Concentration 
Protein concentrations were determined photometrically by the method Gill and von 
Hippel. The molar extinction coefficients ( e Gdnci) can be calculated using the 
formula: 
e Gdnci = A ( £ T y r ) + B ( £ T y r ) + C{ 8 C y s ) 
Where e Tyr, e Tyr and e Cys are the molar extinction coefficients of tyrosine, 
tryptophan, and cysteine residues at the wavelength of 280nm. The A, B, and C are 
the number of each type of residue in each protein. The e Tyr, e Tyr and £ Cys are 
1280, 5690, and 120M''cm'', respectively. The optical density of the sample 
denatured in 6M GdnCl was measured at 280nm (Absoinci), and the molar 
concentration (C) of the sample calculated according to 
C ( i n M ) = AbSGInCI / £ GdnCl 
The concentration unit can be converted conventionally by the following formula: 
C (in mg/ml) = C (in M) X Molecular Weight (Da) 
13. Far-UV Circular dichroism spectroscopy 
Far-UV CD spectroscopy provides the structural information of protein backbone 
arrangement, thereby allowing the computation of the average secondary structural 
content inside the protein. All far-UV CD spectroscopic measurements were carried 
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out by JASCO J-720 spectrophotometer at room temperature. The relative content of 
secondary structure elements of the recombinant protein was estimated by CDPro 
package software. The parameters are shown on the table. The measured ellipticity 6 
is converted to mean molar residue ellipticity, [ 6 ]MRE by the formula: 
[E ]MRE (in degcm2dmol-l) : 6> X 100 X Mr/(C X d X NA) 
Where 6 is the measured ellipticity; C is the protein concentration in mg/ml; d is 
the cell path length; Mr is the molecular weight of protein and NA is the number of 
amino acid in protein monomer. 
Parameter Far-UV CD Near UV CD 
[Protein] (mg/ml 0.5 1 
Cell path length (cm) 0.2 1 
Range (nm) 190-260 240-330 
Band Width(nm) 1 1 
Sensitivity (mdeg) 10 5 
Resolution (nm) 0.1 0.1 
Response time (sec) 4 1 
Scan speed (nm/min) 100 50 
Accumulates (times) 5 5 
Table shows the parameters of CD measurements 
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14. Intrinsic Fluorescence Studies of Protein 
Fluorescence spectroscopy provides the structural information on the changes in 
tryptophan microenvironment between wild-type and mutants. In the studies, 4 
tryptophan residues in the N-terminal domain were mutated according to the method 
stated in "Mutagenesis", as a result of that, mutant A, B, C and D were constructed, 
each contained one mutated Trp to Try. The samples were measured in a 1cm path 
length curette at room temperature in the fluorescence spectrometer. 
The intrinsic fluorescence of wild-type protein was measured at concentration 2uM 
with the emission wavelength 310-410nm and the excitation was set to wavelength 
295nm. The slits for excitation of emission were 5nm. 
For the studies of acrylamide quenching effect of intrinsic tryptophan, different 
concentrations of acrylamide were mixed with the mutants and the tryptophan 
intrinsic fluorescence spectrum were measured. The acrylamide was served as a 
quencher and the intensity at 342nm was recorded. The ratio of initial fluorescence 
intensity (Fo) over intensity at each titration point (F) was plotted against the 
quencher concentration to obtain the Standard Stern-Volmer plot. 
In order to give a more clear vision on the quenching effect of each tryptophans in the 
wild type protein, Stern Volmer equation was used to calculate the contribution of 
each Trp in the mutants. The relationship between each mutant and fluorescence 
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intensities was shown in the following equation: 
For mutant A , I totai= IB + I C + I D 
For mutant B , I totai= IA + I C + I D 
For mutant C , I totai= I A + I B + I D 
For mutant D, I totai= I A + I B + I C 
The Itotai was the total fluorescence intensity at 342nm of mutant. IA, IB, IC and ID were 
fluorescence intensity of TrpA，TrpB, Trp C and Trp Dat 342nm. 
The intensity contribution and relative positions of 4 tryptophans were calculated 
from the above equation. 
15. Chemical denaturation stability studies 
The intrinsic fluorescence spectrum of wild-type and 4 Trp-mutated proteins were 
recorded when they were mixed with different concentration of guanidine chloride 
(GdnCl) from 0 to 6.5M. Average emission wavelength X of proteins were 
calculated by the equation: 
N N 
X= Z(IiAi)/ Z ( / / ) 
/ = / 1=1 
The average emission wavelength was affected by the red or blue shifting of the 
spectrum and also the intensity changes of intrinsic fluorescence. The integration of 
all data in the spectra could enhance the signal to noise ratio. Fraction of protein 
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unfolded, Fu, at different GdnCl concentration was calculated by the formula: 
Fu = (yp-y) / (yp-yu) 
In the equation, yp is the minimum average emission wavelength; yu is the maximum 
average emission wavelength and y is the measured average emission wavelength at 
different GldCl concentration. The denaturation curve of protein was constructed by 
Fu against different concentration of GdnCl. 
16. Glucuronidation protein activity assay 
The active protein could be regarded as with proper folding. The activity of UGT was 
tested by the rate of glucuronidation. 1-napthol was used as the substrate and 
UDP-glucuronic acid (UDPGA) was co-substrate. Before studying the activity of 
protein, a standard curve was plotted. The mixture of standard curve was similar to 
those in the activity assay except no protein was added. The standard plot was used to 
show the Kd of the enzyme by referring the fluorescence intensity of the substrate and 
the amount of protein amounts. 
In the activity assay, the reaction mixtures contained O.IM Tris, 3mM UDPGA, 5mM 
MgChand 50uM 1-napthol. The mixtures were pre-incubated in 37。C for 10 minutes. 
After that, various amounts of the protein were added to the mixtures and water was 
added to bring the volume to 1 ml. The reaction were carried out in 37°C for 30 
minutes and stopped by adding lOOul of O.IM NaOH. 
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17. Mutagenesis 
The method of mutagenesis was based on the protocol of Stratagene. One pair of 
sense and antisense primers was generated for each mutation site. Each mutagenic 
primer contained the mutation site in the middle and there were around 15 nucleotides 
flanked the site at both sides. A phosphate group was added to the 5 end of the primer. 
Pfu DNA polymerase was used in the generation of mutation. The protocol of PCR 
was shown as below. 
1. 94�C for 2 min 
2. 94°C for 30s 
3. 55°C for 30s 
4. 72�C for 10 min 
5. Repeat Step 2 to Step 4 for 20 cycles 
6. 72�C for 10 min 
7. 4°C forever 
A linear DNA fragment with the length of whole plasmid was amplified and the ends 
were ligated to give back a circular plasmid with T4 DNA ligase. The plasmid was 





There were 11 mutations done in which their charged residue was mutated, i.e. E46A, 
E61A, K75A, E84A, D85A, E118A, K129A, K131A, D143A, D148A, K159A 
Also, there were 4 mutants with tryptophans mutated to tyrosine, i.e. W38Y, W64Y, 
W98Y and W208Y. 
18. Western Blotting for the presence of protein 
The mutants were transformed into the bacteria and expressions were induced. The 
bacteria were harvested and lysed with 1% SDS. Ten microlitres of each whole cell 
lysate were mixed with lOul 2X loading buffer and loaded to the SDS-PAGE. 
The nitrocellulose membrane was soaked with 100% methanol for 5 minutes and 
equilibrated in transfer buffer for 10 minutes. 
The proteins in the SDS-PAGE were transferred on the nitrocellulose with semi-dry 
transfer cell at 15 voltages for 60 minutes. The membrane was washed with TBS-T 
and blocked with 1% skimmed milk in TBS-T. After that the membrane was coupled 
with primary antibody, anti-Xpress, for 60 minutes. Then the membrane was washed 
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with TBS-T and bound with the HRP labeled secondary antibody. 
ECL Western Blotting Detection Kit was used for detection of signal. The mixture A 
and B were mixed in a 1:1 ratio and incubated the membrane for 5 minutes. The 
excess detection reagent was drained off and put it in an X-ray film. The signal was 
detected by exposing on an autoradiography film. The film was developed and fixed 
for visualization of signal. 
19. Protein Modeling with Insight II 
19,1. Construction of substrate 1-napthol structure 
The 1-napthol structure was constructed using the 2D Sketcher in the module 
MolBuilder of Insight II. The MolBuilder dialog box contained 3 parts: the Elements 
which used to specify the atom in the bonding, the Bonds/Rings which was used to 
draw different ring structures like 5C, 6C or 8C etc and define the stereochemistry of 
bonds, and the remaining part contained the 2D-3D structure convertion and energy 
optimization of the chemical. 
The 2D structure of 1-napthol was first drawn. The two 6-carbon rings were sketched 
from the Bonds/Rings and the oxygen atom was added to the -OH group in the 
Element part. After the 2D structure was sketched, stereochemistry of the bonds was 
defined and the structure was converted to the 3D one. The program would carry the 
steps automatically. The last step was to optimize the 3D structure that included the 
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computation of energy of the structure and minize energy level and force by 
alternating the position of atoms. The complete 3D structure was saved as NAP.CAR 
by the PUT command under the MOLECULAR menu. 
19.2 Obtaining UDP-glucuronic acid in PDB file 
The Protein Data Base file of UDP-glucuronic acid was downloaded from the internet 
with experiment coordination in the file. 
19.3 Obtaining rat UGT1A8 model structure in PDB file 
The PDB file of rat UGTl A8 model structure was downloaded from ModBase of 
UCSF (University of California, San Francisco). The model was based on template 
structure of glycosyltransferase which shared 14% sequence homology and with E 
value of le-59 (it showed the alignment between the target and template sequences by 
NCBI BLAST program). The model score of the structure was 1, which was higher 
than a cutoff value (0.7). The results provided information for a reliable model with a 
probable correct fold larger than 95%. 
19.4 Optimization of rat UGT1A8 structure 
First the module BIOPLOYMER was chosen. The forcefield was set to 
charmm27.cfrc in the CHARMM. The UGT1A8 structure was loaded into the 
program as a PDB file. Hydrogen atoms were omitted in PDB file and they must be 
added back before further processing. The HYDROGEN command under MODIFY 
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menu was used to fulfill the task. Also the N and C terminal ends of the peptide were 
needed to be capped and COO- was capped on C-terminus with HN3 was set to 
N-terminus. That process was done by the CAP command in the PROTEIN pulldown 
menu. 
In the modeling process, the protein was assumed to be soaked in solvent with a 
certain cutoff distance with neighbors, i.e. the protein is in a cell. To understand the 
dimensions of the cell, the lengths of the protein in each coordinate were listed by the 
LIST command in the MOLECULE menu. The cell box was a cubic with all sides 
equal in length, so the length of the longest coordinate side, after addition of 1 OA as a 
cutoff value, was chosen to be the length of the cell box. The parameters of defining a 
cell could be found in the CELL command in the ASSEMBLY pulldown menu, in 
which the LENGTHS was the calculated length of the cubic and all ANGLES were 
set as 90.0. CENTER IN CELL was toggled on to locate the protein at the center of 
the cell. After a cell was defined, the solvent was added back to the cell to simulate 
the in vivo environment and water was the chosen solvent. 
After a cell was set up, the atomic potential types and partial charges were calculated 
before starting a molecular mechanics calculation. In the POTENTIALS command 
under the FORCEFIELD icon, the POTENTIAL ACTION and the PARTIAL CHG 
ACTION were set as FIX; while the FORMAL CHG ACTION was set as ACCEPT. 
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Then the POTENTIALS command was executed. 
Beside potential and partial charges, hydrogen bond interactions between peptide and 
surrounding solvent were also taken into consideration. The HBOND command in the 
MEASURE menu helped to do the task. 
After finishing the settings, a solvated system was created and optimization works 
was done on the system. CHARMm was used to minimize and run dynamics on the 
system. To set the MINIMIZATION METHOD, STEEPEST DECENTS was chosen 
and the NUMBERS OF STEPS was left to the default value of 100. All other settings 
remained unchanged and then selected EXECUTE. 
After setting the parameters of minimization, those of dynamics were set in the 
DYNAMICS command in the SETUP pulldown menu. 
Firstly, the heating phase was set. For the TEMPERATURE CONTROL, HEAT was 
toggled on and the TARGET TEMPERATURE was set to 300.0. All other settings 
were left as their default value and then the settings were executed. 
Secondly the equilibration phase was set. The EQUILIBRATE of the 
TEMPERATURE CONTROL was toggled on in the DYNAMICS SETUP parameter 
box. The TIME STEP was set as 0.001 picoseconds and TARGET TEMPERATUE 
was 300. All other settings were left as their default value and then the settings were 
executed. 
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The final phase was the setting of simulation phase. The SMULATE for 
TEMPERATURE CONTROL was toggled on and the DYNAMICS ENSUMBLE was 
set to NVT. The TIME STEP and TARGET TEMPERATURE were 0.001 
picoseconds and 300 respectively. The NUMBER OF STEPS was set to 1000 and the 
parameters were executed. 
After setting of the parameters, the simulation was ready to run. The 
CHARMM RUN command from the CHARMM RUN menu was selected. 
RUN—MINIMIZE and RUN—DYNAMICS were toggled on and also STEEPEST 
DESCENTS and the three dynamics phases. The USE PBC was toggled on so the 
water solvent profile could be loaded for calculation. EXECUTE was selected to 
launch the simulation. 
19.5 Docking studies of interaction between ligands and protein 
19.5.1 Setting up a Grid 
A grid was part of the protein in which the nonbonded energetic was precalculated. It 
had the benefit of time and energy saving when simulating the interaction of ligand 
and protein as the ligand might be moving in the proposed binding site to search for 
the best position. The grid helped to save the works and to calculate the whole protein 
by just working on the residues included in the grid. 
The forcefield cvff.frc was selected for docking and the protein was loaded into the 
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program by the RESTORE—FOLDER command. 
To set up a grid, the DOCKING module was selected and CREATE was clicked from 
the DOCKING_GRID menu. The GRID_STYLE was set to ENCLOSURE to 
produce a box that included the whole molecule. The GRID STEP was set to 0.666 
and the command would start automatically while the molecular name entered the 
MOLECULE SPEC. From the console, there were around 760000 grid points to be 
calculated. 
Afterwards the value of each grid point was calculated. The COMPUTE command 
was selected from the DOCKING_GRID menu. Both VAN—DER—WAALS and 
COULOMB were toggled on and the CUT OFF was set to 15. MAKE—VIS GRID 
was toggled on also and the parameters were executed. 
19.5.2 Docking of 1-naothol to UGT1A8 
After the grid was calculated, the substrate 1 -napthol was loaded into the program by 
the GET command in the MOLECULE menu. The color of 1-napthol was set to a 
different color from that of protein for easier recognition. The proper position of the 
ligand in respect to the protein was determined by the intermolecular energy. To show 
the energy, the INTERMOLECULAR command was chosen from the EVALUATE 
menu. The MONITOR was toggled on and the MONITOR MODES was set to ADD. 
GRID was toggled on and the CUT OFF value was set as 8 Angstorms. After 
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executing the command, the energy would be shown on the upper right-handed corner 
of the monitor. To move the ligand in relative to the protein, the CONNECT 
command was selected from the TRANSFORM menu. After the command was 
loaded, the position of the ligand could be controlled by the buttons combination and 
movement of the mouse. 
19.5.3 Docking of UDP-glucuronic acid to the complex of UGTlA8 and 1-napthol 
With the finding of the position with lowest energy level, the substrate, 1-napthol, was 
assumed to couple to the right place of the protein and it was associated with the 
protein, UGTl A8, to form a complex. The energy minimization and dynamics 
calculations were performed on the complex using the CHARMM module. After the 
calculation, the UDPGA molecule was loaded into the program as a PDB file. The 
UDPGA was set to move in relative to the complex by the CONNECT command and 
the docking procedures were just similar to those of 1-napthol. 
19.5.4 Definition of Subsets 
A subset included the atoms or residues that were near the bound ligand. Two subsets 
were defined in the project, one for 1-napthol and one for UDPGA. To define a subset, 
the INTERFACE command was selected from the SUBSET menu. For the 
MOLECULE PICK LEVEL, the file name of substrate was filled in; while the protein 
name was filled in the SEARCH_DOMAIN. The COLLECTION LEVEL was set to 
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MONOMER/RESIDUE with the RADIUS OF SUBSET set to 10. 
To list the content of a subset, the LIST command from the SUBSET menu was 
selected and filled in the name of subset that wants to be shown in the SUBSET LIST. 
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Chapter 3 Results 
RNA was extracted from the rat liver tissue (Figure 3.1). Three bands were visible 
from the gel in each sample. The uppermost band was the 28S RNA. The middle band 
was the 18S RNA and the lowest band was the 6S RNA. The absence of smear and 
the approximate ratio of 28S: 18S was equal to 2:1 indicating that the RNA was of 
good quality and underwent no degradation. The samples were ready for further 
experiments. 
After the cDNA was made from RT-PCR of RNA, the cDNA was used as the template 
for amplification of UGTl A8 gene. Figure 3.2 showed the content of PCR product, a 
sharp, clear and specific band in the DNA gel with the approximate size 1500b 
represented the UGTl A8 gene that was used for amplification. The gene was cloned 
into expression vector and the vector was transformed into DN5 a . Three clones with 
cells which contained the vector were selected and grown for plasmid extraction 
(Figure 3.3). Subsequently, the sequence of the gene was checked. The commercial 
DNA sequencing service was provided by Tech Dragon HK Ltd. The sequencing was 
carried out with three primers, i.e. T7: TAA TAC GAC TCA CTA TAG GG, T7-term: 
CTA GTT ATT GCT CAG CGG T and 157-F: TCT TGC CAA GTA CTT TTC TC. 
The sequence was aligned and checked with NCBI Blast program. The result (Figure 
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3.4) showed the cloned gene was rat UGTl A8 with 100% homology with the 
sequence in the database. 
The gene was expressd in E. coli JM109 (DE3) with different temperature and time 
duration (Figure 3.5) and the expression profile was showed in Figure 3.6. The 
appearance of protein band with the size around 55kDa in the lysate of IPTG-induced 
cell samples but not in non-induced sample showed that the UGT1A8 protein was 
successfully expressed (40). 
The protein was purified with Ni-column and gel filtration column. The partially 
purified protein after Ni-column affinity chromatography (Figure 3.7) was further 
subjected to gel filtration chromatography. The elution profile was showed in Figure 
3.8. Three major peaks were present with a small peak in the profile. Some protein 
could be degraded during the preparation and purification. The eluent (60ml) was 
collected. The purification profile was showed in Figure 3.9. The profile showed the 
continuous purification of the protein from non-purified cell lysate. Subsequently, the 
partially purified protein from Ni-column and finally purified protein was obtained. 
The single band with the size around 55kDa indicated the presence of purified 
UGT1A8. 
The sequences of several members in the UGTl A family were chosen to test for their 
sequence similarity. The sequence after amino acid residue 286 of UGTl A8 was 
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identical among other members but the N-terminal parts varied in different members. 
However, the members in the same subclass like UGTl A7 and UGTl A8 shared very 
high homology in N-terminal sequence and the 2D structure prediction by software 
JUFO of UGTl A8 could be implied to that of UGTl A7 also. The predicted 2D 
structure content was �70o/o alpha,�150/0 strand and �150/0 random (Figure 3.10). 
The purified protein was characterized by circular dichroism (CD) (Figure 3.11). 
Far-UV CD spectrum was recorded in Figure 3.11a and it was used to study the 
secondary structure content of the protein. The secondary content of UGTl A8 was 
calculated with the CDPro software package. The results showed the protein had high 
alpha helix content with around 45% and relatively less B-strand content in the 
protein structure, which accounted for around 17% only. The Near-UV CD spectrum 
(Figure 3.1 lb) was used to study the absorption of aromatic amino acid, i.e. Phe, Tyr 
and Trp, in the protein. The spectrum recorded a strong signal at 270nm to 300nm 
which associated Try and Trp. 
To study individual residues towards the function of UGTl A8, 11 positively charged 
residues were mutated. Those residues were chosen based on the prediction that the 
charged group may interact with the hydroxy 1 group of the substrate, 1-napthol. 
Figure 3.12 showed the western blotting of wild-type protein and mutants, the 
presence of the band indicated the successful expression of the protein. Apart from 
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those with charged residue mutated proteins, 4 Trp mutants, W38Y, W64Y, W98Y and 
W208Y, were also tested for their enzyme activities. For a total of 16 proteins, their 
expression levels were similar to those as shown by the band intensity except mutant 
K129A. There was no detectable activity with K129A in the bacteria and probably the 
protein was not able to be expressed with unknown reason. 
The mutants were tested for the enzyme activities and compared the differences 
between the mutant and wild type protein. Table 3.1 showed the averaged 
glucuronidation activity rate of each enzyme towards 1-napthol. The value was 
standardized with the amount of proteins expressed. The difference between the 
mutant and wild type protein was represented as the percentage of activity changed. 
E84A and D85A had their activities decreased for more than 10% than that of 
wild-type. The activities decreased 22% and 18%, respectively. For Trp mutants, 
W208Y showed a drop in activity for more that 20%. 
To get some insights into the structure property of UGTl A8, the fluorescence spectra 
of E84A and D85A were examined (Figure 3.13) and the peak positions were 
compared with the wild type protein. The peak positions of wild type, E84A and 
D85A were 344.5, 344.1 and 344.7, respectively. Also, 4 tryptophan residues were 
mutated and W38Y, W64Y, W98Y and W208Y were constructed. Figure 3.14 showed 
the fluorescence spectrum of the wild type and 4 Trp mutants. The peak positions of 
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WT, W38Y, W64Y, W98Y and W208Y were 344.7nm, 345.8nm, 346.0nm, 347.2nm 
and 342. Inm, respectively. The spectrum of W38Y, W64Y and W98Y were 
red-shifted while that of W208Y was blue-shifted. The shifting was correlated with 
the stability of the protein. From the result, mutation in Trp38, Trp 64 and Trp98 
destabilized the structure, however, mutation in Trp208 made the protein more rigid. 
Chemical denaturation studies of wild type and mutants were carried out to test the 
stabilities of mutants. Figure 3.15 showed the denaturnation curve of these proteins. 
The curve shifting represented the degree of variation of stability. Increasing 
concentrations of GdnCl disrupted the tertiary packing and affected the average 
fluorescence emission wavelength. The shifting with lower GdnCl concentration 
represented a decrease in stability. The mid-curve of the curve represented the 
concentration of the GdnCl that was required for unfolding 50% of protein, indicating 
the relative stability of the protein W208Y> WT>W3 8 Y> W64 Y>W98 Y. 
Resolved Stern-Volmer plot in Figure 3.16 showed the quenching effect of various 
concentrations of acrylamide on the 4 Trp residues. Under the same concentration of 
acrylamide, the Trp with higher fluorescence intensity ratio indicated the residue was 
located closer to the surface of the protein. On the other hand, the Trp with lowest 
intensity ratio meant it was located in a relative innermost position of the protein. 
As a result of the quenching test, the intensity ratio under a particular acrylamide 
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concentration was W3 8Y>W98Y>W64Y>W208Y. 
In order to investigate the glucuronidation reaction of UGT more clearly, computation 
modeling was done to simulate the interaction of the UDP-glucuronic acid and 
1-napthol with the UGT1A8 protein. The UGT1A8 protein structure was proposed 
and optimization was done. The model was done with surrounding condition 
simulation, energy minimization and molecular dynamics. In Figure 3.17, the 
optimized UGT1A8 model was shown in ribbon format. The model was subjected to 
clocking with 1-napthol, which was the substrate. Afterwards, the co-substrate, 
UDP-glucuronic acid was added to the complex. Interaction regions of the protein 
were defined as subsets and the residues were listed out for possible interaction. 
Figure 3.18 showed the UDP-glucuronic acid and the proposed interacting region of 
the protein that was colored in blue. The residues that may take part in the interaction 
included 34-39, 81-86,146,171,304-309,334-336,369-374. These amino acids 34-39, 
81-86,146,171 are in the N-terminal domain. Figure 3.19 showed the interaction of 
the 1 -napthol with UDP-glucuronic acid and UGT. The protein region which may be 
involved in the interaction with 1-napthol was colored in pink. The residues included 
34，81, 83, 84, 93, 95, 96, 146, 307-310 of UGT. 
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Figure 3.1. The extracted RNA from rat liver tissue. 
Lanes 1 to 8 showed the eight RNA samples which were extracted from the rat liver 
tissue. The RNA after extraction was subjected to gel electrophoresis and 3 ug of 
RNA was loaded into each gel. The gel was run under 130V for 13 minutes. The gel 




Figure 3.2. DNA gel of PCR amplified gene product. 
Lanes 1 to 5 represented the PCR products of gene amplification. PCR products (2ul) 
were mixed with lul of loading dye. The mixture was loaded to each well of the 1% 
0.5 X TBE DNA gel containing 0.1% ethidium bromide. The band at the right was the 
DNA marker and the others were PCR products. The gel was run at 150V for 17 
minutes. The photo was taken from the GelDock system. 
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Figure 3.3. Colony PCR of UGTlAS-pRSetB transformed DH5 a bacteria. 
The lOObp marker was on the left-handed side of the photo and other lanes on the 
right were PCR products. Each sample mixture contained 4ul of PCR products and 
lul of DNA Loading Dye. The 1% 0.5 X TBE DNA gel was subjected to 
electrophoresis under 130V for 20 minutes. The gel was soaked into 0.1 % ethidium 
bromide. The photo was taken in GelDock system. 
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Figure 3.5. SDS-PAGE of cell lysates with different expression temperature and 
time duration 
Lane 1: Benchmark Protein Ladder 
Lane 2: non-induced cell lysate 
Lane 3: induced cell lysate (3hours at 25°C) 
Lane 4: induced cell lysate (Shours at 25°C) 
Lane 5: induced cell lysate (3hours at 37�C) 
Lane 6: induced cell lysate (Shours at 37�C) 
Bacterial cells were induced for protein expression with different temperature and 
time duration. Cell lysates (lOul) were mixed with lOul of 2 X SDS-PAGE Loading 
Buffer. Samples (20ul) were loaded into the well 2 to 6 and the marker (6ul) was 
loaded into the well 1. 
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Figure 3.6. SDS-PAGE of bacterial cells lysates. 
Lane 1: lysate of non-induced cells 
Lane 2: lysate of 3hrs induced cells (UGTlAS-pRSetB plasmid transformed) 
Lane 3: lysate of 5hrs induced cells (UGTlAS-pRSetB plasmid transformed) 
Lane 4: lysate of induced cells (pRSetB plasmid transformed) 
Lane 5. Benchmark Protein Ladder 
Cell lysates (lOul) were mixed with lOul of 2 X SDS-PAGE Loading Buffer. Samples 
(20ul) were loaded into the well 1 to 4 and the marker (6ul) was loaded into the well 5. 
The gel was run under 175V for 1 hour. The gel was stained with 0.5 % Coomassie 




Figure 3.7. SDS-PAGE of Ni-column eluted protein. 
Land: Collected eluted fraction 1 
Lane2: Washed fraction 
Lane3: Non-induced bacterial cell lysate 
Lane4: Benchmark Protein Ladder 
Cell lysates (lOul) were mixed with lOul of 2 X SDS-PAGE Loading Buffer. Eluted 
proteins were precipitated out with acetone solution and dissolved in 50ul of 2 X 
SDS-PAGE Loading Buffer. Samples (20ul) were loaded into the well 1 to 3 and the 
marker (6ul) was loaded into the well 4. 
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Figure 3.8. Elution Profile of Gel Filtration Chromatography. 
The elution profile was recorded and analyzed with the UNICON software. The UV 
detection was set at 280nm. The flow rate was set at Iml/min and each fraction was 
collected at 1.5ml. 
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Figure 3.9. SDS-PAGE analysis of UGTl A8 fractions from Ni-column and gel 
filtration column. 
Lane 1: Benchmark Protein Marker 
Lane 2: Eluted Fraction 1 of Ni-column 
Lane 3: Eluted Fraction 2 of Ni-column 
Lane 4: Eluted Fraction 3 of Ni-column 
Lane 5: Eluted Fraction 4 of Ni-column 
Lane 6: Protein collected after gel fraction column 
Each sample mixture contained precipitated protein sample and 1 Oul of sample 
loading buffer. The protein was precipitated with acetone solution. The gel was run 
with 175V for Ihr. Afterwards, it was stained with 0.5% Comassise Blue solution for 
3 hours and distained with 10% acetic acid and 30% ethanol. 
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1 a8 -MAPSGCPPSLPLCVaFLASG---FAQAGRLLWPMDGSHWFTMQMIVEKLSHRGHEW 56 
1 a7 -MAPADIPASLPLGLCLLLASG- - -FGHAGKLLWPMDGSHWFTMQMWEKLLPKGHEW 56 
1 al MSWCRSSCSLLLLPCLLLCVLGPSASHAGKLLVIPIDGSHWLSMLGVIOOLQQKGHEW 60 
1 a6 --MAaLPAARLPAGFLFLVLWG--SVLGDKLLWPQDGSHWLSMKEIVEHLSERGHDIV 56 
UUUUUUUHHHHHHHHSSSHHH HHHUUUSSSSSSUUUUUHHHHHHHHHHHHHUUUSS 
1 a8 WIPEVSWHMGKSLNFTVKTYSVSYTLEDLNYHFKFFAHNQWKTQEVG-MFSLLKHSGKG 115 
la7 \WEVSWQLGKPLNF™TYSVSHTQEDLNRERFFTDSQWKT0QEGGVLPLLTSPAQG 116 
1 al VIAPEASIHIKEGSFYTMRKYPVPFQNENVTMFVELGRSVFDQDPFLLRWKTYNKVKR 120 
1 a6 VLVPEVNLLLGESKYYRRKSFPVPYNLEELRTRYRSFGNNHFMSSPLMAPLREYRNNMI 116 
SSSSSUUUUUUUUUUSSSSSSSSSUUUUUUUUHHUUUUUUUUUUUUUU ITJUHHHHHHHH 
1 a8 FFELLFSHCRSLFKDKKLVEYLKQSSFDAVFLDPFDVCGLILAKYFSLPSWFSGGIFCH 175 
1a7 FFELLFSHCRSLFKDKKLVEYLKQSSFDAVFLDPFDVCGLTVAKYFSLPSVVFSRGIFCH 176 
1 a1 DSSMLLSGCSHLLHNAEFMASLEQSHFDALLTDPFLPCGSTVAQYLSLPA\WLNALPCS 180 
1a6 VIDMCFFSCQSLLKDSATLSFLRENQFDALFTDPAMPCGVILAEYLKLPSIYLFRGFPCS 176 
HHHHHHHHHHHHHUUHHHHHHHUUUUSSSSSSSUHHHHHHHHHHHHUUUSSSSUUUUHHH 
1a8 YLDEGAQCPSPPSYVPRILSKFTDTMTFKERWNHLSYMKERAFCPYFFKTAVEIASEVL 235 
1a7 YLEEGSQCPSPPSYVPRGILKLTDTITFKERVWNLLSYMGEHAFCPSFFKTATOIASEVL 236 
1 a 1 LDLEATQCPAPLSYVPKSLSSNTDRMNFLQRVKNMI lALTENFLCRWYSPYGSLATEIL 240 
1 a6 LEHMLGQSPSPVSYVPRFYTKFSDHMTFPQRLANFIAN丁LENYLYHCLYSKYEILASDLL 236 
HHHHHUUUUUUUUUUUUUUUUUUUUUUHHHHHHHHHHHHHHHUUUUUUUUUHHHHHHHUU 
1 a8 grPVTMRDLFSPVSIWMFRTDFVLEFPRPVMPNMVYIGGINCHQGKPLSKEFEAYVNASG 295 
1 aV QTPVTMmFSPVSVWLLRTDFTLELPRPWNVIHIGGINCHQRKPLSKEFEAYVNASG 296 
1al QKEVTVKDLLSPASIWLMRNDFVKDYPRPIMPNMVFIGGINCLQKKALSQEFEAYVNASG 300 
1 a6 KRDVSLPALHQN-SLWLLRYDFWEYPI^WNMIFTGGTOCKKKGNLSOEFEAYVNASG 295 
UUUUHHHHHHHHHHHHHHUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUHHHHHHHHUUU 
1a8 TEHGIWFSLGSMVSEIPEKKAMEIAEALGRIPQTVLWRYTGTRPSNLAKNTTLVKWLPQN 355 
1 a7 EHGTVWSLGSMVSEIPEKKAMEIAEALGRTPQmWRYTGTRPSNLAKNTILVKWLPQN 356 
1 al EHGIWFSLGSMVSEIPEKKAMEIAEALGRIPQTVLWRYTGTRPSNLAKNTILVKWLPQN 360 
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1 a6 EHGIWFSLGSMVSEIPEKKAMEIAEALGRIPQTVLWRYTGTRPSNLAKNTILVKWLPQN 355 
UUSSSSSSSUUUUUUHHHHHHHHHHHHHHHUUSSSSSSSSUUUUUUUUUUSSSSSSUUUH 
1 a8 DLLGHPKARAFITHSGSHGIYEGICNGVPMVMMPLFGDQMDNAKRMETRGAGVTLNVLEM 415 
la7 DLLGHPKARAFITHSGSHGIYEGICNGVPMVMMPLFGDQMDNAKRMETRGAGVTLNVLEM 416 
lal DLLGHPKARAFITHSGSHGIYEGICNGVPMVMMPLFGDQMDNAKRMETRGAGVTLNVLEM 420 
la6 DLLGHPKARAFITHSGSHGIYEGICNGVPMVMMPLFGDQMDNAKRMETRGAGVTLNVLEM 415 
HHHUUUUUUSSSSSUUUUUHHHHHHUUSSSSSSSUUUUUHHHHHHHHHHSSSSSSSUUUUU 
1 a8 TADDLENALKTVINNKSYKENIMRLSSLHKDRPIEPLDLAVFWVEYVMRHKGAPHLRPM 475 
1 a7 TADDLENALKTVINMSYKENTMRLSSLHKDRPIEPLDLAW\VVEYVMRHKGAPHLRPAA 476 
1 al TADDLENALKTVINNKSYKENIMRLSSLHKDRPIEPLDLAWWVEYVMRHKGAPHLRPM 480 
1 a6 TADDLENALKTVINNKSYKEIVIMRLSSLHKDRPIEPLDLAVFWVEYVMRHKGAPHLRPM 475 
UHHHHHHHHHHHHUUUUHHHHHHHHHHHHHHUUUUHHHHHHHHHHHHHHUUUUUUUUUUU 
1 a8 HDLTWYQYHSLDVIGFLLAIWTVWi™SCAYGCRKCFGGKGR\TCKSHKSKra 530 
1 a7 HDLTWYQYHSLDVIGFLLAIVFTWFIVYKSCAYGCRKCFGGKGRVKKSHKSm 531 
lal HDLTWYQYHSLDVIGFLLAIVLTWFIVYKSCAYGCRKCFGGKGRVKKSHKSKTH 535 
1a6 HDLTWYQYHSLDVIGFLLAIVLTWFIVYKSCAYGCRKCFGGKGRVKKSHKSKTH 530 
UUUUUUUUUUUHHHHHHHHHHHHHHHHHHHHHHUUUUUUUUUUUUU 
Figure 3.10. Sequence Alignment of UGTs in the rat UGTl A family and 2D 
structure prediction of UGTl A8. 
The alignment of UGTl Al, UGT1A6, UGT1A7 and UGT1A8 was done with 
CLUSTAL W software. The secondary structure of UGTl A8 predicted by software 
JUFO was stated below the sequences. H, S and U represent helix structure, strand 
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Figure 3.11. Circular Dichroism (CD) measurement on rat UGT1A8. 
(a) Far-UV CD spectrum of UGT1A8 and calculated secondary structural 
contents. 
The spectrum was recorded at room temperature at 0.2cm path length. The experiment 
was carried out at room temperature. The contents of secondary structure were 
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(b) Near-UV CD spectrum of UGTl A8. 
The absorbance range for particular aromatic acid side chain was labeled at the 
bottom of near-UV spectrum. The experiment was carried out at room temperature, 
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WT is the wild type protein and Lanes 1 to 11 was mutant proteins. Primary antibody, 
Anti-Xpress Epitope, was used for the detection of proteins. The transfer of protein to 
the nitrocellulose and blotting process were carried out in room temperature. The 
transfer was made under 15V for Ihr. 
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Average Standardized 





E84A 0.91 ±0.06 
D85A 0.96±0.04 
E118A 1.15 士 0.05 
K129A  
K131A 1.14±Q.Q5  
D143A 1.19±0.08 
D148A 1.17±0.04 
K159A 1.21±Q.07  
W38Y 1.09 土 0.08 
W68Y 1.03±0.07 
W98Y 1.04 土 0.06 
W208Y 0.89±0.05 
Table 3.1. The specific activity of wild type and the mutants. 
The activity was measured by the changes in fluorescence intensity of the substrate, 
1-napthol. The measurement was carried out at room temperature and the slit lengths 
of emission and excitation were set at 2.5. Each measurement was taken 3 times and 
the average value was recorded (Table 1). 
N.D. meant the activity was not detectable. 
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Figure 3.13. Fluorescence spectrum of wild type and two charged-residue 
mutants of UGTl A8. 
The spectrum was recorded with excitation wavelength at 295nm and the emission 
wavelength range started from 310nm to 410nm. The fluorescence studies were 
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Figure 3.14. Fluorescence spectrum of wild type and Trp mutants of UGTl A8. 
The spectrum was recorded with excitation wavelength at 295nm, which was the 
specific excitation wavelength for Trp. The fluorescence emission spectrum was 
recorded in the range of 31 Onm-41 Onm 
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Figure 3.15. Chemical denaturation of wild type and Trp-mutated UGT1A8 
proteins. 
The denaturation study was carried out with a fluorescence spectroscopy. The 
emission spectrum was scanned from 310nm to 410nm with excitation wavelength 
295nm. The study was carried out in room temperature and 3 readings for each 
protein were taken for data analysis. 
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Figure 3.16. Resolved Stern-Volmer plot of UGT1A8 on acrylamide quenching. 
The plot showed the influence of fluorescence intensity on individual Trp in the 
presence of various concentrations of acrylamide. The lo and li represented excited 
Trp fluorescence intensity Trp at 342nm in the presence and absence of acrylamide 




Figure 3.17. The 3D modeling structure of rat UGT1A8. 
The structure was shown in a ribbon format without substrate and co-substrate. The 
molecule was set in an environment soaked in water with dielectric constant 80 and 
temperature was 300K. Energy minimization and molecular dynamics work were 
done on the model. 
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Figure 3.18. Modeling simulated the interaction between UDP-glucuronic acid 
and UGT1A8. 
The blue region was the defined subset which indicated the residues located within 
lOA from the UDPGA. The simulation condition was worked out at temperature 
300K and solvent dielectric constant 80. The position and direction of the UDPGA 
were determined by the lowest energy state. 
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Figure 3.19. Modeling simulated the interaction between UDP-glucuronic acid, 
1-napthol and UGT1A8. 
The blue and pink regions were the defined subsets which indicated the residues 
located within 1 OA from the UDPGA and 1 -napthol, respectively. The simulation 
condition was worked out at temperature 300K and solvent dielectric constant 80. The 
position and direction of the UDPGA were determined by the lowest energy state. 
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Chapter 4 Discussion 
1. Successful Expression of Rat UGT1A8 
In search of ways to express the protein, several vectors and bacterial cell strains were 
tested to prepare sufficient amount of the protein with high homology for the study, as 
the bacteria lack the mechanism of post-translational modification. Also, the bacterial 
expression of the protein could allow us to produce a pure protein efficiently. 
In the present study, vectors with different tags and promoters were tested for the 
efficiency of protein expression. The UGT1A8 gene was cloned to each vector using 
the methods described in the cloning section of Chapter 2 with a few modifications on 
restriction site choosing. The expression vector with lac promoter, pMal-c2x, and 
BL21 were tested for the expression. The vector carried a malE gene, which encoded 
for a MBP tag, might help to enhance the solubility of recombinant protein. However, 
there was no observable protein expression which might yield a large molecular size 
of recombinant protein (�lOOkDa). 
Subsequently, a vector with T7 promoter, which was a stronger promoter, was chosen. 
Expression vectors pET52b and pRSet were tested. The pET52b vector contained 2 
tags, i.e. 6 X His-tag and Strep tag, while pRSet vector got 6 X His-tag only. BL21 
(DE3) bacterial cell strain was used. The protein was expressed as an inclusion body 
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with pRSet vector, while pET52b vector failed in expression. The difference in 
expression efficiency might be due to the variation of tag which might affect the 
quantity and solubility of recombinant protein. After these experiments, 
UGTlA8-pRSet B vector was used for expression. However, the insoluble form of 
UGT1A8 failed to refold to native form as shown by the complete loss of enzyme 
activity so different cell strains were tested to achieve soluble expression of the 
protein. 
Bacterial cell strains, BL21 (DE3), JM109 (DE3) and O r i g a m p M 2(DE3), were 
investigated. As mentioned before, the inclusion body was produced in BL21 (DE3). 
However, the soluble protein was found in the other 2 cell strains in which JM109 
(DE3) gave a higher quantity. The variation of expression in these cell strains might 
be due to different origins. BL21 (DE3) was B strain background but JM109 (DE3) 
and OrigamiTM 2(DE3) were derived from K12 strain. The expression profile in 
JM109 (DE3) was presented in Figure 3.5 and Figure 3.6. 
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2. The recombinant rat UGT1A8 protein was properly folded with enzymatic 
activity 
After the successful expression of the recombinant protein, characterization of the 
protein was done. The properties of the protein including molecular weight, folding 
order, consistency with computation prediction and functional assay were performed. 
Figure 3.9 shows the protein was in soluble form as only soluble fraction of cell lysate 
was loaded to the Ni-column and the protein was successfully eluted. Also, the 
molecular weight of the protein was around 55kDa which was in agreement with the 
published data (40). Besides, the presence of the protein band in western blot analysis 
(Figure 3.12) showed the successful expression. 
After that, the function assay of the recombinant UGT1A8 was carried out. The 
specific activity of the UGTl A8 protein in supernatant fraction of E. coli whole cell 
lysate was found to be 1.17±0.06 nmol/min/mg proteins (Table 3.1). The specific 
activity was very similar to that of recombinant protein expressed in mammalian cell 
line in which the rate was 1.23 士 0.12 nmol/min/mg proteins (40). The results showed 
the protein correctly folded with the activity similar to mammalian one. 
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3. Purified recombinant rat UGT1A8 protein contained well-ordered structure 
The protein purity for fluorescent spectroscopy and CD experiment are above 80%. 
The purity of rat UGT1A8 protein should be high enough for the characterization 
study. As a result, the protein in the supernatant of bacterial cell lysate was subjected 
to Ni-column, which partially purified the protein by coupling of His-tag to resins, 
and size exclusive chromatography. Figure 3.9 showed the high purity of the protein 
after these steps. The activity of the protein was tested to detect any changes in pre 
and post-purified enzyme. The specific activity was determined to be 0.68 士 0.07 
nmol/min/mg proteins. There was a drop in the activity (�40o/o) while compared to 
that of non-purified protein with 1.17±0.06 nmol/min/mg proteins (Table 3.1). The 
decrease in activity might be due to the deterioration of tertiary packing of protein 
during the purification and concentration steps. 
To study structural changes of the protein, circular dichroism experiments were done. 
The secondary structure of the protein was computed (Figure 3.10) which contained 
�56o/o helix,�20o/o strand and �24o/o turn/random structure. When the experimental 
data from Far-UV CD (Figure 3.1 la) was compared with that of computational, the 
contents were similar except with lower helix content so the structure of protein might 
still be orderly packed. The high helix content might be caused by computation error 
in which there were cases with miscalculated random structure into helix. 
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In order to further examine the protein structure with a well-ordered packing, near-UV 
CD was used. The spectrum (Figure 3.11b) showed a strong absorption peak from 
270nm to 300nm and indicated the tyrosine and tryptophan residues of the protein 
were in rigid asymmetric environments. The asymmetric environment reflects the 
structural integrity of the protein. If the protein contains a packed structure, the 
rotation and movement of amino acid would be limited and result in an asymmetric 
position of the amino acid, it will lead to strong UV absorption. The presence of the 
peak indicated the protein was in an orderly packed tertiary structure instead of an 
unordered globule form. 
104 
4. Relative positions of Trp38，Trp64, Trp98 and Trp208 in the protein 
Four tryptophan residues, Trp38, Trp64, Trp98 and Trp208, were chosen in this study. 
They belonged to the N-terminal domain of the protein. The relative position of each 
tryptophan residue in respect to other 3 residues was determined by acrylamide 
quenching experiments. The experiment based on the ease of exposure of the Trp to 
the surrounding and resulted in higher quenching effect brought by dissolved 
acrylamide in the solvent. When the concentration of acrylamide increased, the 
protein started to unfold and so Trp residues were exposed in an order related to their 
position in the protein. These changes in the Trp microenvironment could be detected 
by intrinsic fluorescence spectroscopy. 
The resolved Stern-Volmer plot (Figure 3.16) described the relative positions of the 4 
Trp. According to the result, Trp38 was located at the outermost region of the protein 
where the fluorescence intensity was quenched effectively by acrylamide in the 
solvent, while Trp208 was located at the relatively innermost area. Trp98 and Trp64 
were at the location in-between Trp38 and Trp208. 
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5. Contribution of Trp residues in the folding and stability of the protein 
The impact of individual tryptophan residues to the structure of protein was 
investigated with intrinsic fluorescence spectroscopy and chemical denaturation 
studies. 
The fluorescence spectrum of the four Trp-mutants and wild-type protein were shown 
in Figure 3.14. The intensities of mutants were lower than that of wild-type due to 
loss of one tryptophan residue. The relative decrease in the intensity of W208Y in 
comparison with other Trp-mutants indicated that Trp208 was more important in 
maintaining tertiary structure. 
The importance of each Trp to the structure stability could be recognized from the 
shifting pattern of the peak position of the mutant's fluorescence spectrum. The 
results showed the peak positions of W38Y, W64Y and W98Y shifted towards longer 
wavelength, i.e. red-shifted. It indicated the decrease in stability of mutants. The 
spectrum of W38Y was least shifted (l . lnm) while that of W64Y and W98Y were 
similar (�2nm). However, the peak position of W208Y was blue-shifted from 
344.7nm to 342. Inm, which means the structure of mutant is more rigid than the 
wild-type. The mutation of Trp208 could enhance the packing of protein structure. 
To further study the impact of tryptophan residues to the structure of protein, chemical 
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denaturation of mutants and wild-type proteins and then their fluorescence spectrum 
were recorded (Figure 3.15). The fraction of unfold (u) indicated the amount of 
protein denatured in a given concentration of GdnCl. The stability of the proteins 
could be determined from the concentration of GdnCl required to unfold 50% of the 
total protein. The order of stability of mutants and wild-type proteins were 
W208Y>WT>W38Y>W64Y>W98Y. 
The effect of these tryptophan residues on enzymatic activity was studied (Table 3.1). 
Mutation of Trp208 leaded to the decrease of activity (�23o/o) while mutations on 
other Trp caused no significant change. 
The study is consistent with the results of acrylamide quenching. Trp208 played an 
important role in maintaining the feasibility of the protein and the feasibility could 
contribute to the coupling of substrate into the binding pocket of the protein. Trp64 
and Trp98 were more important than Trp38 in the tertiary packing of protein probably 
due to the inner core location of these 2 Trp when compared to that of Trp38. 
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6. Probing of substrate coupling region by mutagenesis 
The binding of substrate involved both N and C terminal domains and in order to 
probe for the coupling location of the substrate in the N-terminal domain, mutagenesis 
was done. The substrate, 1-napthol, contained a -OH group and might interact with 
charged residues, so 11 charged resides were mutated to non-charged alanine. After 
that, the enzymatic activity assay was done for these mutants. Table 3.1 showed E84A 
and D85A with reduced activity �22o/o and -18%, respectively. The decrease in the 
activity suggests that these residues might be involved in the binding region. 
To determine if the effect of the mutation on the activity was due to the charge on the 
residues or structural changes caused by mutations, intrinsic fluorescence spectrum of 
E84A, D85A and wild-type protein were recorded and shown in Figure 3.12. The 
peak positions of wild-type, E84A and D85A were 344.5, 344.1 and 344.7nm, 
respectively and the degrees of shifting were small. The result indicated the stability 
of the mutants was not significantly affected. 
As a result, the drop in activity of E84 and D85 mutants was probably caused by the 
charge-carrying properties of these residues and might be involved in the interaction 
between protein and substrate. 
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7. Interaction studies of substrate and UDP-glucuronic acid with UGT1A8 by 
computer modeling and docking simulation 
The docking positions and orientations of the substrate and UDPGA were determined 
by the manual adjustment to achieve the lowest energy. In Figure 3.17, the substrate, 
1-napthol, was docked into the inner part of cavity and the co-substrate, UDPGA, was 
located near the opening of the cavity. The relative positions of those ligands were 
similar to that of DP-epi-Vancosaminyltransferase GtfA (83). The relative positions of 
these 2 substrates were defined by achieving low energy. The energy of grid in the 
protein complex contained UGT and 1 -napthol and that of complex contained UGT, 
1-napthol and UDPGA were -8.53cal/mol and -10.748cal.mol, respectively. The 
negative value of energy represented that the protein complex was energetically 
favorable with high stability. Also, similar energy levels obtained in the complex of 
UGT and 1-napthol (-8.53cal/mol) and the complex with additional UDPGA 
(-10.748cal/mol) showed the docking of these two substrates was favorable and did 
not cause a significant variation in the protein structure. 
As shown in the Figure 3.18 and 3.19, residues were located within lOA. They might 
take part in the interaction between 1-napthol and UGT. The residue E84 was one of 
the amino acids in the region. Also, residues 81-86 were believed to play a role in the 
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interaction between UDPGA. The 2 charged residues, E84 and D85, that were 
believed to be involved in important in the activity of the enzyme (Table 3.1), were 
within that region. The modeling computational results were consistent with the 
experimental data. The results suggest E84 and D85 were involved in ligand binding 
and important in the function of the UGT. Besides that, the modeling also suggests the 
oxygen atoms of -COO group be responsible for the interaction. 
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Chapter 5 Conclusion 
The rat UGT1A8 protein was successfully expressed in bacterial cell JM109(DE3). 
The expressed protein retained a high activity which was similar to that expressed in 
mammalian cell line. However, the purification and concentration steps deteriorated 
the protein and resulted in a decrease in activity. Fortunately, the variation in activity 
did not markedly affect the tertiary packing of the protein during the investigation on 
the structure by CD spectroscopy. 
Characterization of the protein was done. Trp208 was shown to maintain the 
feasibility and played a role in ligand binding. Trp38 was not important in both 
structure and function as it was located near the surface of the protein. 
Besides, site-directed mutagenesis was carried out to identify residues that were 
probably associated with the ligand binding. E84 and D85 were shown to be involved 
in the binding. The mutation of them resulted in a drop of the activity. However, these 
residues did not have notable effect on the structure of the protein. Also, the computer 
docking of the substrates and the protein was consistent with the experimental data. 
Also, the computer modeling and simulation on ligand binding suggest several 
regions of the protein might be involved in the binding. They were amino acids 34-39, 
81 -86,146,171,304-309,334-336,369-374. These residues might interact with 
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UDP-glucuronic acid. Other amino acids 34, 81，83, 84, 93, 95, 96, 146, 307-310 
were believed to interact with 1-napthol. 
Further works like alanine scanning were needed to confirm those residues that were 
responsible for the ligand interaction. Also, more mutation works were necessary to 
prove E84 and D85 involve in the ligand binding through charge interaction. Apart 
from that, improvement and refinement on the purification and concentration 
conditions were needed to enhance the functional study of the protein. 
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